Dr. Kettani is the founder of the United Nations Pathology Anatomy Center located in Rabat and project leader for the future pathology laboratory of the International Hospital of Rabat. He is also a senior member of several scientific entities in Morocco and is a leader in the development of prostate cancer diagnostic technologies in Morocco, establishing himself as a valuable partner in the development.
DeepDX from DeepBio, which has been introduced in Morocco, has been meticulously verified through collaboration with major research institutions such as the Stanford University School of Medicine and has shown a high agreement rate among professional urological pathologists.
It has furthermore demonstrated a sensitivity of 99% and a specificity of 97%, indicating that it has the potential to improve clinical decision-making.
Additionally, DeepDX Prostate has the unique advantage of being able to provide insightful diagnostic reports to urologists and patients by integrating AI-based analysis with the conclusions and final evaluation of the pathologist.
By actively using the reports provided, one can establish the future treatment plan for a patient and effectively enhance the decision-making process, thereby contributing to the provision of personalized treatment for patients.
Kim Seon-woo, CEO of Deep Bio, stated: “The introduction of Deep Bio’s Prostate in Morocco will mark an important milestone for Deep Bio in its expansion into new markets.” He added: “This will contribute to improving the diagnosis of prostate cancer in the country.”
Transforming Prostate Cancer Diagnosis in North Africa with AI Technology
The introduction of DeepDX, an innovative diagnostic tool developed by DeepBio, marks a significant milestone in the realm of medical technology in North Africa. With the guidance of Dr. Fouad Kettani, a leading oncologist based in Rabat, this advanced system aims to revolutionize prostate cancer diagnosis through artificial intelligence.
Dr. Kettani, recognized for his expertise and leadership in cancer diagnostics, has been instrumental in integrating this technology into clinical practice. His role as the founder of the United Nations Pathology Center and project leader for the future Rabat International Hospital’s pathology lab exemplifies his commitment to enhancing healthcare standards in Morocco.
DeepDX stands out due to its collaborative development with esteemed institutions like Stanford University, proving its accuracy with an impressive 99% sensitivity and 97% specificity. This high degree of reliability positions DeepDX as a critical asset for urologists and pathologists in the region.
A unique feature of DeepDX Prostate is its ability to generate insightful diagnostic reports that amalgamate AI analysis with traditional pathology conclusions. This integration not only enhances the clarity and effectiveness of diagnostic outcomes but also equips healthcare providers to formulate personalized treatment plans tailored to individual patient needs.
As noted by Kim Seon-woo, CEO of Deep Bio, the rollout of DeepDX in Morocco signals the company’s strategic expansion into new markets, reflecting a growing recognition of the importance of technological advancements in medical diagnostics. This not only promises to improve patient outcomes but also positions Morocco as a prospective leader in implementing cutting-edge healthcare solutions in North Africa.